Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Hum Cell. 2021 Jul;34(4):1266-1273. doi: 10.1007/s13577-021-00548-6. Epub 2021 May 15.
Myxofibrosarcoma (MFS) is one of the most aggressive sarcomas with highly complex karyotypes and genomic profiles. Although a complete resection is required in the treatment of MFS, it is often not achieved due to its strong invasive nature. Additionally, MFS is refractory to conventional chemotherapy, leading to poor prognosis. Therefore, it is necessary to develop novel treatment modalities for MFS. Patient-derived cell lines are important tools in basic research and preclinical studies. However, only 10 MFS cell lines have been reported to date. Furthermore, among these cell lines, merely two MFS cell lines are publicly available. Hence, we established a novel MFS cell line named NCC-MFS3-C1, using a surgically resected tumor specimen from a patient with MFS. NCC-MFS3-C1 cells had copy number alterations corresponding to the original tumor. NCC-MFS3-C1 cells demonstrate constant proliferation, spheroid formation, and aggressive invasion. In drug screening tests, the proteasome inhibitor bortezomib and the histone deacetylase inhibitor romidepsin demonstrated significant antiproliferative effects on NCC-MFS3-C1 cells. Thus, the NCC-MFS3-C1 cell line is a useful tool in both basic and preclinical studies for MFS.
黏液纤维肉瘤（MFS）是一种侵袭性很强的肉瘤，具有高度复杂的核型和基因组特征。尽管在治疗 MFS 时需要完全切除肿瘤，但由于其强烈的侵袭性，往往无法实现。此外，MFS 对常规化疗具有抗性，导致预后不良。因此，有必要为 MFS 开发新的治疗方法。患者来源的细胞系是基础研究和临床前研究的重要工具。然而，迄今为止仅报道了 10 种 MFS 细胞系。此外，在这些细胞系中，仅有两种 MFS 细胞系可供公开使用。因此，我们使用一名 MFS 患者的手术切除肿瘤标本建立了一种新的 MFS 细胞系，命名为 NCC-MFS3-C1。NCC-MFS3-C1 细胞具有与原始肿瘤相对应的拷贝数改变。NCC-MFS3-C1 细胞表现出持续的增殖、球体形成和侵袭性。在药物筛选试验中，蛋白酶体抑制剂硼替佐米和组蛋白去乙酰化酶抑制剂罗米地辛对 NCC-MFS3-C1 细胞表现出显著的抗增殖作用。因此，NCC-MFS3-C1 细胞系是 MFS 基础和临床前研究的有用工具。
